ProBioGen & Surface Oncology sign second antibody development project

German service and technology provider, ProBioGen, and immune-oncology company, Surface Oncology, have signed a second antibody development project for the development and manufacture of another antibody for potential use in clinical trials.

Under the terms of the agreement ProBioGen will develop several stable cell lines in parallel, gradually reduce the candidate number and conclude with process development and GMP manufacturing for a single antibody product candidate. The advantage of this approach is the analysis of several candidates at the same time while also strongly reducing time lines.

“We have worked together with Surface Oncology very well for quite a while and this is now our second potential clinical antibody project together,” commented ProBioGen’s CBO, Dr Gabriele Schneider. “We have established a seamless team working across our companies and we are very pleased to continue to expand this relationship with Surface Oncology.”